Status:
COMPLETED
Macrophage-mediated Inflammation in White Adipose Tissue and Non-alcoholic Fatty Liver Disease.
Lead Sponsor:
Imperial College London
Conditions:
Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
18+ years
Brief Summary
Non-alcoholic fatty liver disease (NAFLD) is present in one third of the population and due to its potential to cause irreversible liver damage and liver cancer, it is a significant health burden. The...
Detailed Description
NAFLD is a huge health burden and can lead to liver damage,scarring and cancer, therefore gaining a further understanding of the mechanisms involved in causing liver damage is particularly important t...
Eligibility Criteria
Inclusion
- Bariatric and Upper Gastrointestinal (UGI) surgery patients classified as obese or morbidly obese (BMI \>30)
- Patients who attend UGI cancer services with a BMI \<25
Exclusion
- Participants with:
- alcohol consumption more than 10g of ethanol per day
- viral Hepatitis infection
- HIV
- Autoimmune condition
- genetic liver disease
- other metabolic causes of liver disease
- abnormal clotting
- immunosuppressive medication
- drugs that are known to precipitate hepatic steatosis.
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 5 2023
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04059068
Start Date
September 1 2019
End Date
September 5 2023
Last Update
December 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College NHS Trust
London, United Kingdom, W2 1NY